Collegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call Transcript Summary
Collegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call Transcript Summary
Financial growth was particularly strong in the Pain portfolio, and Jornay PM is expected to generate over $100 million in net revenue in 2024.The following is a summary of the Collegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call Transcript:
以下是 Collegium Pharmaceutical, Inc. (COLL) 2024年第三季度業績會 記要：
Financial Performance:
財務表現:
Collegium reported record total net product revenues of $159.3 million in Q3 2024, up 17% year-over-year.
Adjusted EBITDA was a record $105.1 million, up 18% year-over-year.
Financial growth was particularly strong in the Pain portfolio, and Jornay PM is expected to generate over $100 million in net revenue in 2024.
Collegium 報告2024年第三季度總淨產品營業收入爲15930萬美元，同比增長17%。
調整後的EBITDA創下了10510萬美元的記錄，同比增長18%。
財務增長在疼痛產品組合方面表現尤爲強勁，預計 Jornay Pm 在2024年將產生超過10000萬美元的淨收入。
Business Progress:
業務進展:
Completed the acquisition of Ironshore, integrating Jornay PM into the ADHD market.
Jornay PM prescriptions increased 31.2% year-over-year, highlighted by back-to-school season growth.
Introduced new CEO Vikram Karnani, a seasoned biopharmaceutical executive, to lead future growth and expansion.
完成了對Ironshore的收購，並將Jornay Pm整合到多動症市場中。
Jornay Pm處方同比增長31.2%，以返校季節增長爲特色。
引入經驗豐富的生物製藥高管維克拉姆·卡納尼擔任新首席執行官，領導未來增長和擴張。
Opportunities:
機會：
Integration of Ironshore's Jornay PM broadens Collegium's commercial presence into the large ADHD market, enhancing revenue diversification beyond pain management.
將Ironshore的Jornay Pm整合到學院的商業業務中，拓展到龐大的ADHD市場，增強營業收入多元化，超越疼痛管理。
Risks:
風險：
No explicit risks detected.
沒有發現任何明確風險。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
